Aslan Pharmaceuticals Ltd (ADR)

General ticker "ASLN" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $11.8M

Aslan Pharmaceuticals Ltd (ADR) does not follow the US Stock Market performance with the rate: -38.6%.

Estimated limits based on current volatility of 6.8%: low 0.53$, high 0.61$

Factors to consider:

  • Earnings for 6 months up through Q2 are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2023-12-31 to 2025-12-30

  • 2023-12-31 to 2024-12-30 estimated range: [2.52$, 9.32$]
  • 2024-12-30 to 2025-12-30 estimated range: [1.89$, 6.17$]

Financial Metrics affecting the ASLN estimates:

  • Negative: Non-GAAP EPS of -8.20 <= 0.08
  • Negative: Operating Income to Revenue ratio of -0.78 <= 0.01
  • Negative: negative Net Income
  • Negative: Operating Cash Flow per share of -2.82 <= 0.20
  • Negative: Industry Operating Cash Flow per share (median) of -1.55 <= 0.28
  • Negative: Industry Earnings per Price (median) of -0.25 <= 0.01

Similar symbols

Short-term ASLN quotes

Long-term ASLN plot with estimates

Financial data

YTD 2021-12-31 2022-12-31 2023-12-31
Operating Revenue $0.00MM $0.00MM $12.00MM
Operating Expenses $33.85MM $47.88MM $55.74MM
Operating Income $-33.85MM $-47.88MM $-43.74MM
Non-Operating Income $2.26MM $-3.40MM $-0.34MM
Interest Expense $1.86MM $3.68MM $4.33MM
R&D Expense $22.02MM $38.00MM $42.50MM
Income(Loss) $-31.59MM $-51.28MM $-44.08MM
Taxes $3.12MM $0.10MM $0.14MM
Profit(Loss) $-34.71MM $-51.38MM $-44.22MM
Stockholders Equity $57.30MM $8.37MM $-13.29MM
Assets $94.52MM $61.19MM $24.63MM
Operating Cash Flow $-34.00MM $-38.41MM $-46.36MM
Investing Cash Flow $-0.03MM $0.41MM $-0.01MM
Financing Cash Flow $109.87MM $4.72MM $10.72MM
Earnings Per Share* $-2.66 $-3.68 $-2.69

* EPS are Split Adjusted, recent splits may be reflected with a delay.